PharmaRoth Labs, Inc. (ROTH)

[sweetlou]

Here is some additional supporting information on metformin, the most prescribed oral medication worldwide for type 2 diabetes:
Despite the position of international diabetes associations and leading experts in the field that metformin is the preferred initial and foundational agent for the treatment of type 2 diabetes, approximately 40 percent of the 18 million treated patients in the United States are not benefiting from metformin therapy. The two most common reasons cited by physicians are contraindication due to renal impairment, and gastrointestinal intolerance that leads to discontinuation or dose reduction.
The above considerations are the impetus for studying a delayed release form of metformin to minimize those effects. Those same considerations would warrant use of an alternative to metformin to achieve better control of HbA1C and fasting plasma glucose without the side effects and concerns with renal impairment (potentially fatal lactic acidosis due to inability of the kidneys to excrete metabolites of metformin)
Based on previous study results, Sucanon may be a viable alternative.